Literature DB >> 14615713

Complications in infants hospitalized for bronchiolitis or respiratory syncytial virus pneumonia.

Douglas F Willson1, Christopher P Landrigan, Susan D Horn, Randall J Smout.   

Abstract

OBJECTIVE: To characterize complications among infants hospitalized for bronchiolitis or respiratory syncytial virus (RSV). STUDY
DESIGN: Retrospective data from 684 infants with bronchiolitis or RSV pneumonia, < or =1 year old, admitted to 10 children's hospitals from April 1995 to September 1996. Outcomes included complication rates and effects on hospital and pediatric intensive care unit (PICU) length of stay (LOS) and hospital costs.
RESULTS: Most infants (79%) had one or more complication, with serious complications in 24%. Even minor complications were associated with significantly longer PICU and hospital LOS and higher costs (P<.001). Respiratory complications were most frequent (60%), but infectious (41%), cardiovascular (9%), electrolyte imbalance (19%), and other complications (9%) were common. Complication rates were higher in former premature infants (87%), infants with congenital heart disease (93%), and infants with other congenital abnormalities (90%) relative to infants without risk factors (76%). Infants 33 to 35 weeks gestational age (GA) had the highest complication rates (93%), longer hospital LOS, and higher costs (P<.004) than other former premature infants.
CONCLUSIONS: Complications were common in infants hospitalized for bronchiolitis or RSV pneumonia and were associated with longer LOS and higher costs. Former premature infants and infants with congenital abnormalities are at significantly greater risk for complications. Broader use of RSV prevention should be considered for these higher-risk infants.

Entities:  

Mesh:

Year:  2003        PMID: 14615713     DOI: 10.1067/s0022-3476(03)00514-6

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  35 in total

Review 1.  Respiratory morbidity and lung function in preterm infants of 32 to 36 weeks' gestational age.

Authors:  Andrew A Colin; Cynthia McEvoy; Robert G Castile
Journal:  Pediatrics       Date:  2010-06-07       Impact factor: 7.124

2.  Risk factors for hospitalization due to respiratory syncytial virus infection among infants in the Basque Country, Spain.

Authors:  G Cilla; A Sarasua; M Montes; N Arostegui; D Vicente; E Pérez-Yarza; E Pérez-Trallero
Journal:  Epidemiol Infect       Date:  2006-06       Impact factor: 2.451

3.  Changes in cardiac output and stroke volume as measured by non-invasive CO monitoring in infants with RSV bronchiolitis.

Authors:  Julie Caplow; Sarah C McBride; Garry M Steil; Jackson Wong
Journal:  J Clin Monit Comput       Date:  2012-04-24       Impact factor: 2.502

4.  Rebuttal: palivizumab for the prevention of respiratory syncytial virus infection.

Authors:  Kelly A Smart; Krista L Lanctôt; Bosco A Paes
Journal:  Can Fam Physician       Date:  2010-10       Impact factor: 3.275

5.  A decade of respiratory syncytial virus epidemiology and prophylaxis: translating evidence into everyday clinical practice.

Authors:  Bosco A Paes; Ian Mitchell; Anna Banerji; Krista L Lanctôt; Joanne M Langley
Journal:  Can Respir J       Date:  2011 Mar-Apr       Impact factor: 2.409

6.  Letters to the Editor.

Authors:  Karen Chang; Dennis Gurwitz; Peter Azzopardi; Shaheen Doctor; Ronik Kanani; Constantine Petrou; Paul Meinert; Meera Umamaheswaran Kissoon
Journal:  Paediatr Child Health       Date:  2016 Jun-Jul       Impact factor: 2.253

7.  Chest physiotherapy using passive expiratory techniques does not reduce bronchiolitis severity: a randomised controlled trial.

Authors:  Isabelle Rochat; Patricia Leis; Marie Bouchardy; Christine Oberli; Hendrika Sourial; Margrit Friedli-Burri; Thomas Perneger; Constance Barazzone Argiroffo
Journal:  Eur J Pediatr       Date:  2011-09-17       Impact factor: 3.183

8.  Severe bronchiolitis in infants born very preterm and neurodevelopmental outcome at 2 years.

Authors:  Marion Gouin; Sylvie Nguyen; Christophe Savagner; Francoise Troussier; Géraldine Gascouin; Jean-Christophe Rozé; Cyril Flamant
Journal:  Eur J Pediatr       Date:  2013-01-22       Impact factor: 3.183

Review 9.  Clinical relevance of prevention of respiratory syncytial virus lower respiratory tract infection in preterm infants born between 33 and 35 weeks gestational age.

Authors:  X Carbonell-Estrany; L Bont; G Doering; J-B Gouyon; M Lanari
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-07-16       Impact factor: 3.267

10.  Palivizumab: a review of its use in the protection of high risk infants against respiratory syncytial virus (RSV).

Authors:  Joseph M Geskey; Neal J Thomas; Gretchen L Brummel
Journal:  Biologics       Date:  2007-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.